Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

Executive Summary

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

You may also be interested in...



iTeos Says Adios To IDO And Eyes US IPO

An oversubscribed financing round led by new US investor MPM Capital has brought in $75m for the Belgian company. Much of it will be used to advance its potential best-in-class adenosine A2A receptor now that its IDO1 drug has been shelved.

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug

Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel